Novimmune and Genentech enter exclusive licence agreement for rheumatoid arthritis drug

Swiss Biotech firm Novimmune has entered into an option and licence agreement with Roche company Genentech to develop and commercialise its anti-toll-like receptor 4 (TLR4) monoclonal antibody, NI-0101, to treat rheumatoid arthritis and other auto-im …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news